Disease · MONDO_0005712

congenital nystagmus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. congenital nystagmus. Diseases, record MONDO_0005712. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005712

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: congenital nystagmus; Open Targets
Open Targets ID: MONDO_0005712; Open Targets
Other names: Involuntary, rapid, rhythmic eye movements, Nystagmus, congenital idiopathic nystagmus, congenital pathologic nystagmus, motor congenital nystagmus, nystagmus, congenital; Open Targets
Disease Ontology: DOID:9649; Disease Ontology
MeSH: D020417; MeSH
Orphanet: ORPHA:651; Orphanet
Highest stage of its drugs: Phase 2, for 1 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NERAMEXANE MESYLATE	CHEMBL2106798	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GRIN1	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116444	Drugs and targets
CACNA1A	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Unknown	https://conductscience.org/library/genes/773	Drugs and targets
CACNA1B	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Unknown	https://conductscience.org/library/genes/774	Drugs and targets
CACNA1C	Voltage-gated calcium channel	1	Voltage-gated calcium channel modulator	Unknown	https://conductscience.org/library/genes/775	Drugs and targets

1 to 10 of 35

See all 35 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00928954	Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus	Not applicable	10	2016-07-29	Nystagmus	GABAPENTIN, MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT00661440	Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus	Phase 2	48		Nystagmus, Congenital Idiopathic, Nystagmus, Acquired	NERAMEXANE MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT00799942	Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus	Phase 2	48		Nystagmus, Congenital, Nystagmus, Acquired, Multiple Sclerosis	NERAMEXANE MESYLATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Gabapentin vs Memantine: serious adverse events	0 of 10	0 of 10	20	NCT00928954

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005712

GET https://conductscience.org/api/diseases/v1/MONDO_0005712/targets?page=2

API reference For AI assistants